Clear Trail Advisors LLC Makes New $1.34 Million Investment in AbbVie Inc. $ABBV

Clear Trail Advisors LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,856 shares of the company’s stock, valued at approximately $1,338,000.

A number of other institutional investors also recently modified their holdings of the company. Chelsea Counsel Co. purchased a new position in AbbVie during the 3rd quarter valued at about $26,000. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the 3rd quarter worth approximately $31,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the 2nd quarter worth approximately $26,000. Caitlin John LLC bought a new stake in shares of AbbVie in the 3rd quarter worth approximately $33,000. Finally, Redmont Wealth Advisors LLC purchased a new position in shares of AbbVie during the third quarter valued at approximately $41,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Down 0.1%

NYSE ABBV opened at $204.89 on Tuesday. The firm has a market capitalization of $362.29 billion, a PE ratio of 86.82, a P/E/G ratio of 0.71 and a beta of 0.34. The stock’s 50 day moving average is $222.79 and its 200 day moving average is $224.80. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ABBV. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and upped their target price for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Guggenheim restated a “buy” rating on shares of AbbVie in a report on Thursday, March 12th. Barclays started coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price for the company. Finally, UBS Group reduced their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $253.15.

Insider Activity

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.08% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.